Xiaoyu Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyu Guo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bowen Yang
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publication - Ce Li
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China
1 shared publication - Danni Li
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China
1 shared publication - Dongni Wang
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publication - Fuqiang Zhang
Department of Anorectal Surgery, the First Hospital of China Medical University, Shenyang, China
1 shared publication - Ruichuan Shi
Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publication
Latest Publications
- Open Access
- 10 January 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-23
ANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74
Background Microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) patients are the dominant population in immune checkpoint blockade treatments, while more than half of them could not benefit from single-agent immunotherapy. We tried to identify the biomarker of MSI-H CRC and explore its role and mechanism in anti-PD-1 treatments. Tumor-specific MHC-II was linked to a better response to anti-PD-1 in MSI-H CRC and CD74 promoted assembly and transport of HLA-DR dimers. Methods The characteristic gene was screened by data analysis of single-cell and bulk transcriptome sequencing from public datasets. MSI-H CRC cells co-cultured with peripheral blood mononuclear cells and syngeneic model in C57BL/6 mice were performed to detect the sensitivity to anti-PD-1 treatments respectively. Results ANXA10 was identified as a characteristic gene of MSI-H CRC and its expression was obviously greater in MSI-H than MSS CRC. ANXA10 significantly sensitized MSI-H CRC to anti-PD-1 treatments in vitro and in vivo. Specifically, ANXA10 promoted HLA-DR dimers in and on the surface of MSI-H CRC by increasing CD74 expression. Besides, this work demonstrated that ANXA10 contributed to better clinical benefits with anti-PD-1 therapy in MSI-H CRC patients. Conclusions Our results provided a novel molecular marker ANXA10 to identify benefit population of MSI-H CRC for improving efficacy of anti-PD-1 and contributed to selection of treatment strategies.
- 10 January 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-23
Open AccessANXA10 sensitizes microsatellite instability-high colorectal cancer to anti-PD-1 immunotherapy via assembly of HLA-DR dimers by regulating CD74
Background Microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) patients are the dominant population in immune checkpoint blockade treatments, while more than half of them could not benefit from single-agent immunotherapy. We tried to identify the biomarker of MSI-H CRC and explore its role and mechanism in anti-PD-1 treatments. Tumor-specific MHC-II was linked to a better response to anti-PD-1 in MSI-H CRC and CD74 promoted assembly and transport of HLA-DR dimers. Methods The characteristic gene was screened by data analysis of single-cell and bulk transcriptome sequencing from public datasets. MSI-H CRC cells co-cultured with peripheral blood mononuclear cells and syngeneic model in C57BL/6 mice were performed to detect the sensitivity to anti-PD-1 treatments respectively. Results ANXA10 was identified as a characteristic gene of MSI-H CRC and its expression was obviously greater in MSI-H than MSS CRC. ANXA10 significantly sensitized MSI-H CRC to anti-PD-1 treatments in vitro and in vivo. Specifically, ANXA10 promoted HLA-DR dimers in and on the surface of MSI-H CRC by increasing CD74 expression. Besides, this work demonstrated that ANXA10 contributed to better clinical benefits with anti-PD-1 therapy in MSI-H CRC patients. Conclusions Our results provided a novel molecular marker ANXA10 to identify benefit population of MSI-H CRC for improving efficacy of anti-PD-1 and contributed to selection of treatment strategies.